| 摘要 |
<p>Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, their derivatives and analogues are known as inhibitors of HMG-CoA reductase and are used as antihypercholesterolemica. Most of them are produced by fermentation with various kinds of microorganisms belonging to the species of Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium, but some of them are the result of treatment of fermentation products according to the methods of chemical synthesis or products of total chemical synthesis respectively. The above mentioned active substances may be destabilized by numerous exterior factors such as light, heat and pH. Besides, their degradation can be enhanced by interactions with other pharmaceutical ingredients such as fillers, binders, lubricants, slip agents and degradation agents. Therefore, pharmaceutical ingredients and the procedure of a pharmaceutical formulation preparation shall be carefully selected to avoid the above mentioned undesirable interactions and reactions. The submitted invention refers to a stable pharmaceutical formulation intended for healing hypercholesterolemia and hyperlipidemia. More precisely, the subject of invention is a new stable solid pharmaceutical formulation containing the inhibitor of the HMG-CoA reductase as active substance, for example atorvastatin, pravastatin, fluvastatin, and cervastatin or their pharmaceutically acceptable salts.</p> |
